{"id":154750,"date":"2026-11-19T08:35:26","date_gmt":"2026-11-18T23:35:26","guid":{"rendered":"https:\/\/japanir.jp\/en\/ir\/4596-20261119-01_wp_product_announcement\/"},"modified":"2026-11-19T08:35:26","modified_gmt":"2026-11-18T23:35:26","slug":"4596-20261119-01_wp_product_announcement","status":"publish","type":"ir_release","link":"https:\/\/japanir.jp\/en\/company\/company-4596\/ir\/4596-20261119-01_wp_product_announcement\/","title":{"rendered":"Kubota Pharmaceutical Holdings Co., Ltd. Announcement of Start of Final Formulation Manufacturing of Emixstat Hydrochloride (Retakubo) by Consolidated Subsidiary"},"content":{"rendered":"<p>Kubota Vision has begun manufacturing the final formulation of Retakubo, targeting the French market. Preparations for supply via Compassionate Use\/Access (AAC) are underway, and ANSM approval is required. The impact on financial results is expected to be minimal, with further disclosures if additional progress occurs.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4596","jir_company_name":"Kubota Pharmaceutical Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2606\u2606","jir_publication_date":"2026-11-19","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4596-20261119-01.pdf","jir_short_summary":"Kubota Vision has begun manufacturing the final formulation of Retakubo, targeting the French market. Preparations for supply via Compassionate Use\/Access (AAC) are underway, and ANSM approval is required. The impact on financial results is expected to be minimal, with further disclosures if additional progress occurs.","jir_summary":"### News Summary\nKubota Vision, a wholly owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., has commenced manufacturing the final formulation (oral tablets) of Retakubo under Compassionate Use\/Access (AAC) authorization in France. GMP-compliant active pharmaceutical ingredient manufacturing has already started, and the initiation of final formulation manufacturing advances the program to the next stage. Under the supply and license agreement with K\u00d4L, preparations continue toward enabling supply in France, including regulatory approval procedures and distribution readiness.\n\n### Investor Impact and Outlook\nThe start of final formulation manufacturing represents a significant step toward providing the drug to patients via AAC; however, because individual application approval by ANSM is required, the near-term impact on financial results is expected to be minor. Kubota Vision will continue to work with K\u00d4L on regulatory matters for supply realization in France and intends to disclose future progress as appropriate.","jir_financial_highlights":"Unknown: Unknown (Unknown)","jir_category":"","jir_hashtags":"#KubotaPharmaceuticalHoldings, #DrugDevelopment, #CompassionateUse","jir_key_figures":"Start of final formulation manufacturing of Retakubo (date unknown)\nStart of GMP-compliant active pharmaceutical ingredient manufacturing (date unknown)\nANSM approval requirement (individual application)","jir_meta_title":"Kubota Pharmaceutical Holdings: Start of Retakubo Final Formulation Manufacturing in France\uff5cProgress Toward AAC Supply","jir_meta_description":"Kubota Vision, a subsidiary of Kubota Pharmaceutical Holdings Co., Ltd., has begun manufacturing the final formulation of Retakubo. Preparations for supply via AAC are progressing while regulatory procedures with ANSM continue. Financial impact is expected to be minor; further developments will be disclosed as they occur.","jir_og_title":"Kubota Pharmaceutical Holdings: Progress in Start of Final Formulation Manufacturing for Retakubo","jir_og_description":"Kubota Vision announced the start of final formulation manufacturing for Retakubo. Preparations for supply via AAC and related regulatory activities are ongoing; attention now turns to subsequent approval processes.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":59981,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"product_announcement","footnotes":""},"sector":[],"importance":[],"class_list":["post-154750","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Kubota Pharmaceutical Holdings Co., Ltd. Announcement of Start of Final Formulation Manufacturing of Emixstat Hydrochloride (Retakubo) by Consolidated Subsidiary - Japan IR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/japanir.jp\/en\/company\/company-4596\/ir\/4596-20261119-01_wp_product_announcement\/\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4596\/ir\/4596-20261119-01_wp_product_announcement\/\",\"url\":\"https:\/\/japanir.jp\/en\/company\/company-4596\/ir\/4596-20261119-01_wp_product_announcement\/\",\"name\":\"Kubota Pharmaceutical Holdings Co., Ltd. Announcement of Start of Final Formulation Manufacturing of Emixstat Hydrochloride (Retakubo) by Consolidated Subsidiary - Japan IR\",\"isPartOf\":{\"@id\":\"https:\/\/japanir.jp\/en\/#website\"},\"datePublished\":\"2026-11-18T23:35:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4596\/ir\/4596-20261119-01_wp_product_announcement\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/japanir.jp\/en\/company\/company-4596\/ir\/4596-20261119-01_wp_product_announcement\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/japanir.jp\/en\/company\/company-4596\/ir\/4596-20261119-01_wp_product_announcement\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/japanir.jp\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Kubota Pharmaceutical Holdings Co., Ltd. Announcement of Start of Final Formulation Manufacturing of Emixstat Hydrochloride (Retakubo) by Consolidated Subsidiary\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/japanir.jp\/en\/#website\",\"url\":\"https:\/\/japanir.jp\/en\/\",\"name\":\"Japan IR\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/japanir.jp\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kubota Pharmaceutical Holdings Co., Ltd. Announcement of Start of Final Formulation Manufacturing of Emixstat Hydrochloride (Retakubo) by Consolidated Subsidiary - Japan IR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/japanir.jp\/en\/company\/company-4596\/ir\/4596-20261119-01_wp_product_announcement\/","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/japanir.jp\/en\/company\/company-4596\/ir\/4596-20261119-01_wp_product_announcement\/","url":"https:\/\/japanir.jp\/en\/company\/company-4596\/ir\/4596-20261119-01_wp_product_announcement\/","name":"Kubota Pharmaceutical Holdings Co., Ltd. Announcement of Start of Final Formulation Manufacturing of Emixstat Hydrochloride (Retakubo) by Consolidated Subsidiary - Japan IR","isPartOf":{"@id":"https:\/\/japanir.jp\/en\/#website"},"datePublished":"2026-11-18T23:35:26+00:00","breadcrumb":{"@id":"https:\/\/japanir.jp\/en\/company\/company-4596\/ir\/4596-20261119-01_wp_product_announcement\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/japanir.jp\/en\/company\/company-4596\/ir\/4596-20261119-01_wp_product_announcement\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/japanir.jp\/en\/company\/company-4596\/ir\/4596-20261119-01_wp_product_announcement\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/japanir.jp\/en\/"},{"@type":"ListItem","position":2,"name":"Kubota Pharmaceutical Holdings Co., Ltd. Announcement of Start of Final Formulation Manufacturing of Emixstat Hydrochloride (Retakubo) by Consolidated Subsidiary"}]},{"@type":"WebSite","@id":"https:\/\/japanir.jp\/en\/#website","url":"https:\/\/japanir.jp\/en\/","name":"Japan IR","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/japanir.jp\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"related_company_data":{"id":"59981","title":"KUBOTA PHARMACEUTICAL HLDGS CO","ticker":"4596"},"_links":{"self":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154750","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release"}],"about":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/types\/ir_release"}],"replies":[{"embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/comments?post=154750"}],"version-history":[{"count":0,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/ir-release\/154750\/revisions"}],"wp:attachment":[{"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/media?parent=154750"}],"wp:term":[{"taxonomy":"sector","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/sector?post=154750"},{"taxonomy":"importance","embeddable":true,"href":"https:\/\/japanir.jp\/en\/wp-json\/wp\/v2\/importance?post=154750"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}